#United States #Tampa #HVAC Technology #ViroZap #Applied Photonix

ViroZap®: A Game Changer in Indoor Air Disinfection

The fight against airborne pathogens has taken a significant leap forward with the introduction of ViroZap®, the first FDA-cleared Class II medical device for in-duct air disinfection by Applied Photonix. On September 15, 2026, the company announced its commercial launch, making this innovative technology available for a variety of indoor environments, including homes, schools, offices, and healthcare facilities.

Understanding ViroZap®

ViroZap® stands out due to its unique ability to integrate directly into existing HVAC systems, unlike conventional standalone air purifiers that require separate units for each room. This integration allows continuous air treatment throughout entire buildings, ensuring a higher level of safety and convenience.

Developed by Dr. Yogi Goswami, a Distinguished University Professor at the University of South Florida and a prominent member of the Florida Inventors Hall of Fame, ViroZap® utilizes advanced plasmonic photonic technology for air disinfection. Built on third-generation technology, the device operates efficiently at a low energy cost.

How ViroZap® Works

One of the most intriguing aspects of ViroZap® is its utilization of UV-A light instead of UV-C light, which is known to cause skin burns and retinal damage. Moreover, many UV-C systems produce ozone, which can be harmful to lung health. ViroZap® not only avoids these issues but has also been subjected to independent testing that confirms impressive performance statistics:

• - 99.9995% reduction of airborne RNA/DNA viruses
• - 99.9997% reduction of airborne bacteria (both gram-positive and gram-negative)
• - 99.995% reduction of mold and fungal spores
• - Rapid detoxification of volatile organic compounds (VOCs) without ozone byproduct

At an airflow rate of 500 CFM, these reductions indicate that ViroZap® can dramatically enhance indoor air quality by actively disinfecting the air that circulates through HVAC systems.

Designed for Real-World Applications

ViroZap® conforms to important industry standards, specifically ASHRAE 241 and ASHRAE 170, ensuring it can be seamlessly incorporated into various HVAC infrastructures. It is designed to be pressure-drop neutral, allowing it to operate effectively alongside proprietary coated MERV 13 or 15 filters and optional HEPA filter coatings. This versatility makes it suitable for a wide range of settings—from single-family homes to hospitals and commercial buildings.

Terry Murray, Vice President of Sales & Marketing at Applied Photonix, stated, “ViroZap represents a fundamental shift in how we think about indoor air quality — moving from filtration alone to active, continuous disinfection at the source.” This change is timely, considering the increasing awareness of air quality's significant impact on health, particularly in crowded indoor spaces.

Availability and Future Prospects

ViroZap® is currently available for commercial deployment, and Applied Photonix is actively seeking partnerships with distributors and installation experts across the United States and internationally. As air quality and health concerns continue to rise, the demand for such innovative solutions is expected to escalate across various markets, including residential, commercial, educational, and healthcare.

About Applied Photonix

Applied Photonix is at the forefront of developing advanced photonic technologies that target indoor air quality and disinfection. Its flagship product, ViroZap®, is a breakthrough in achieving hospital-grade air safety across numerous environments, ensuring people can breathe easier, whether at home, work, or school.

For more information or partnership inquiries, contact Terry Murray directly at [email protected] or via phone at (828) 808-2955.